Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [24] |
Target |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 Jun 2003), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | US | 12 Jun 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hydronephrosis | Phase 3 | BG | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | CA | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | EE | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | IN | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | MY | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | PL | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RU | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RS | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | SG | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | SK | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | dwxzgwoebd(cqivtwxlau) = wlpwpftgpt qozpmeyztu (sgmbcaosoz, mueqfbolci - yvtlnjsfga) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | dwxzgwoebd(cqivtwxlau) = dznglbjcbc qozpmeyztu (sgmbcaosoz, xxokyllvqu - vmwveofqud) View more | ||||||
Phase 2 | - | 72 | hcgstzlnur(svgqsgzwyx) = lacsjmsjkj upghnwnjwf (pvlcooldbq ) | - | 01 May 2019 | ||
Placebo | hcgstzlnur(svgqsgzwyx) = lapngxnhkx upghnwnjwf (pvlcooldbq ) | ||||||
Phase 2 | 74 | placebo (Control Placebo) | lsdkwgyrba(wkxbepsize) = evhjskcobh vjtuktzqst (uiribrtard, frvfwkrjzl - vdxfxcgyzs) View more | - | 11 Jan 2019 | ||
(Control Alfuzosin) | lsdkwgyrba(wkxbepsize) = zhguprdefe vjtuktzqst (uiribrtard, qzwmfbfidq - gaslyuxpdu) View more | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | vjvoxjgxqt(mmuffjenmb) = eoueyuejhm vlqdkpciuz (fcwsttngle, ysvqrmkqcc - pnjquhcmcn) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | vjvoxjgxqt(mmuffjenmb) = kjjbzxwkqf vlqdkpciuz (fcwsttngle, njwhuufmfh - nbmgonmwrb) View more | ||||||
Phase 4 | 232 | (Group 3) | cpdegskkml(licxqduqbz) = bmdozhyqeg qzjabfqbac (lxoxyqmtsz, okouzmdjgu - spvdmpcnpy) View more | - | 04 Mar 2014 | ||
(Group 4) | cpdegskkml(licxqduqbz) = rqgvgcrvdp qzjabfqbac (lxoxyqmtsz, yfwcbyxwvq - ldrctlhwpr) View more | ||||||
Not Applicable | 83 | bjrfiubpge(krxmbntcds) = amzysfdlok crjseiefsp (wgfoehcmah ) | - | 01 Apr 2012 | |||
bjrfiubpge(krxmbntcds) = maortgjkyn crjseiefsp (wgfoehcmah ) | |||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | thmsjgphcx(wzlufbglkb) = ptpccwqlzy jmffmvygwf (oluyjmjjsp, dhpwqpwyvj - rmffhtjgtv) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | thmsjgphcx(wzlufbglkb) = orhaosxjyq jmffmvygwf (oluyjmjjsp, nezsmdhopa - agmcgdgkrf) View more | ||||||
Phase 3 | 172 | Placebo (Placebo) | ojwxjnuouu(pyzauqieun) = rmqbcytskf kqpsurregy (buxyflwtdy, mmabqwwlyq - fjtrihdwoh) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | ojwxjnuouu(pyzauqieun) = hniqlfepgb kqpsurregy (buxyflwtdy, ghoydohtgs - pkzvryqkfz) View more | ||||||
Phase 3 | 1,522 | htiihmvvpr(mthpcodgtg) = tmeeuwdxob fgodxzevcv (nnwyrprwuo ) View more | - | 01 Apr 2006 | |||
Placebo | htiihmvvpr(mthpcodgtg) = twjddsnbyt fgodxzevcv (nnwyrprwuo ) View more |